Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 10Psoriasis 6Leukemia 5Lymphoma, Follicular 4Myelodysplastic Syndromes 3Inflammation 3Asthma 3Arthritis, Juvenile 3Vasculitis 2Uveitis 2Respiratory Distress Syndrome 2Recurrence 2Prostatic Neoplasms 2Pneumonia 2Neuroblastoma 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Wilms Tumor 1Temporomandibular Joint Disorders 1Stomatitis 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1

Interventions

Vaginal Smears 1Tumor Necrosis Factor Inhibitors 1Radioimmunodetection 1Pregnancy Tests 1Human Papillomavirus DNA Tests 1Etanercept 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Spondylarthritis × Etanercept × Clear all
NCT02364479 2019-12-19

Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein

Sun Yat-sen University

Phase 4 Completed
150 enrolled

Recurrence, Spondylarthritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡